7:35: Before we dive further into these topics tod

Quote:

---

7:35: Before we dive further into these topics today, I would like to briefly touch base on the company's communication strategy. Over the last 18 months, the pendulum has swung completely to the opposite side of where it had been, with regards to our communication strategy. This was the result of some of the regulatory and legal issues the company has been subject to and is still currently working through. We are aware that the pendulum has probably swung too far, and is what tends to happen when adjustments are made. We are in the process of revisiting this strategy and expect to make some changes that we think investors will really appreciate. However, I also do want to take this time to remind everyone that as a publicly traded company, we must be careful with what we communicate and when. And also, that SEC regulations do require us to disclose material events so investors are made aware of them in due course. In particular, announcing the company impressions or conclusions about our communications with the FDA could hurt our chances of resolving issues and undermine our relationship with the FDA which we are hard at work at repairing. I can also assure everyone, although we are not issuing press releases as frequently, that does not mean we are not diligently working on and advancing company initiatives on a daily basis. We continue to be working expeditiously and in good faith to resolve the outstanding issues with the FDA and to advance company objectives.

9:20: We do appreciate everyone's patience with this. We believe that investors will be pleased with some of the communication strategy changes that will be made as a result of the review of our strategy. I will now hand it off to Tanya Urbach, our board chair.

---